Skip to main content

Recent Sentinel Activity

This recent activity feed provides a list of the last 90 days of Sentinel activity across assessments, publications & presentations, projects, events, etc.

RSS Feed

URL Title Category Date Recent Activity
https://www.sentinelinitiative.org/news-events/fda-safety-communications-labeling-changes/fda-labeling-change-keppra-updated-include FDA Labeling Change: KEPPRA Updated to Include Risk of Anaphylaxis and Angioedema Regulatory Impact
FDA Labeling Change: KEPPRA Updated to Include Risk of Anaphylaxis and Angioedema
Regulatory Impact
https://www.sentinelinitiative.org/news-events/publications-presentations/who-gets-treated-influenza-surveillance-study-us-food-and Who Gets Treated for Influenza: A Surveillance Study From the US Food and Drug Administration’s Sentinel System Publications and Presentations
Who Gets Treated for Influenza: A Surveillance Study From the US Food and Drug Administration’s Sentinel System
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/utilization-post-exposure-prophylaxis-prevent-lyme-disease Utilization of Post-Exposure Prophylaxis to Prevent Lyme Disease in a Large US Healthcare Database Publications and Presentations
Utilization of Post-Exposure Prophylaxis to Prevent Lyme Disease in a Large US Healthcare Database
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/using-inpatient-electronic-medical-records-study-influenza Using Inpatient Electronic Medical Records to Study Influenza for Pandemic Preparedness Publications and Presentations
Using Inpatient Electronic Medical Records to Study Influenza for Pandemic Preparedness
Publications and Presentations
https://www.sentinelinitiative.org/methods-data-tools/methods/augmenting-date-death-cause-death-ascertainment-sentinel Augmenting Date of Death & Cause of Death Ascertainment in Sentinel Methods, Data, & Tools
Augmenting Date of Death & Cause of Death Ascertainment in Sentinel
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/incidence-and-prevalence-confounding-variables-over-time Incidence and Prevalence of Confounding Variables Over Time in the Sentinel Distributed Database (SDD): A Descriptive Analysis Analyses
Incidence and Prevalence of Confounding Variables Over Time in the Sentinel Distributed Database (SDD): A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/methods/inclusion-semi-structured-and-unstructured-electronic-health-record-ehr Inclusion of Semi-Structured and Unstructured Electronic Health Record (EHR) Data in Confounding Adjustment and Outcome Ascertainment Methods, Data, & Tools
Inclusion of Semi-Structured and Unstructured Electronic Health Record (EHR) Data in Confounding Adjustment and Outcome Ascertainment
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/methods/development-and-evaluation-electronic-health-record-ehr-information Development and Evaluation of Electronic Health Record (EHR) Information Extraction Pipeline and Tree-Based Scan Statistic (TBSS) Methods for EHR-Based Signal Detection (DA2) Methods, Data, & Tools
Development and Evaluation of Electronic Health Record (EHR) Information Extraction Pipeline and Tree-Based Scan Statistic (TBSS) Methods for EHR-Based Signal Detection (DA2)
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/mortality-following-long-acting-injectable-antipsychotics Mortality Following Long-Acting Injectable Antipsychotics Use: An Inverse Probability of Treatment Weighting Analysis Analyses
Mortality Following Long-Acting Injectable Antipsychotics Use: An Inverse Probability of Treatment Weighting Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/methods/strengthening-inferential-studies-us-fda-sentinel-initiative Strengthening Inferential Studies in the U.S. FDA Sentinel Initiative: A Methodological Demonstration Project Methods, Data, & Tools
Strengthening Inferential Studies in the U.S. FDA Sentinel Initiative: A Methodological Demonstration Project
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/methods/systematic-process-assessing-fitness-purpose-health-outcomes-computable A Systematic Process for Assessing Fitness-for-Purpose of Health Outcomes for Computable Phenotyping with Electronic Health Records Data Methods, Data, & Tools
A Systematic Process for Assessing Fitness-for-Purpose of Health Outcomes for Computable Phenotyping with Electronic Health Records Data
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/methods/empirical-application-sentinel-ehr-and-claims-data-partner-network Empirical Application of the Sentinel EHR and Claims Data Partner Network to Enhance ARIA Sufficient Inferential Requests and Atypical Descriptive Requests (Use Case Package 2) Methods, Data, & Tools
Empirical Application of the Sentinel EHR and Claims Data Partner Network to Enhance ARIA Sufficient Inferential Requests and Atypical Descriptive Requests (Use Case Package 2)
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/occurrence-stroke-intracranial-hemorrhage-and-bleeding Occurrence of Stroke, Intracranial Hemorrhage, and Bleeding Outcomes Following Direct Oral Anticoagulant Use in Patients Aged 64 or Younger with Atrial Fibrillation: A Descriptive Analysis Analyses
Occurrence of Stroke, Intracranial Hemorrhage, and Bleeding Outcomes Following Direct Oral Anticoagulant Use in Patients Aged 64 or Younger with Atrial Fibrillation: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/characterization-influenza-complications-among-individuals-diagnosed-influenza-illness Characterization of Influenza Complications Among Individuals Diagnosed with Influenza‐Like Illness, Pneumonia and Influenza, and Medically Attended Acute Respiratory Illness: A Descriptive Analysis Analyses
Characterization of Influenza Complications Among Individuals Diagnosed with Influenza‐Like Illness, Pneumonia and Influenza, and Medically Attended Acute Respiratory Illness: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/intentional-self-harm-following-glucagon-peptide-1-receptor Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis Analyses
Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/intentional-self-harm-following-glucagon-peptide-1-0 Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis Analyses
Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2021-first Duration of Follow Up for New Molecular Entities Approved in 2021: First Descriptive Analysis Analyses
Duration of Follow Up for New Molecular Entities Approved in 2021: First Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/characteristics-and-drug-utilization-dabigatran-rivaroxaban Characteristics and Drug Utilization in Dabigatran, Rivaroxaban, and Apixaban Initiators Aged 64 or Younger: A Descriptive Analysis Analyses
Characteristics and Drug Utilization in Dabigatran, Rivaroxaban, and Apixaban Initiators Aged 64 or Younger: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/thromboembolic-stroke-intracranial-hemorrhage-0 Thromboembolic Stroke, Intracranial Hemorrhage, Gastrointestinal Bleeding, and Major Extracranial Bleeding Following Apixaban, Dabigatran, and Rivaroxaban Use in Patients Aged 64 Years and Younger with Atrial Fibrillation: An Inverse Probability of Treatment Weighting Analysis Analyses
Thromboembolic Stroke, Intracranial Hemorrhage, Gastrointestinal Bleeding, and Major Extracranial Bleeding Following Apixaban, Dabigatran, and Rivaroxaban Use in Patients Aged 64 Years and Younger with Atrial Fibrillation: An Inverse Probability of Treatment Weighting Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/lyme-disease-prophylaxis-single-dose-doxycycline-united Lyme Disease Prophylaxis by Single-Dose Doxycycline in the United States, 2010–2020 Publications and Presentations
Lyme Disease Prophylaxis by Single-Dose Doxycycline in the United States, 2010–2020
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/trends-single-dose-doxycycline-lyme-disease-prophylaxis Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Second Descriptive Analysis Analyses
Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Second Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/trends-single-dose-doxycycline-lyme-disease-prophylaxis-0 Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Descriptive Analysis Analyses
Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-hormonal-contraceptives-following-live-birth-or Utilization of Hormonal Contraceptives Following Live-Birth or Stillbirth Delivery: A Descriptive Analysis Analyses
Utilization of Hormonal Contraceptives Following Live-Birth or Stillbirth Delivery: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-confounding-covariates-trinetx-descriptive Characterization of Confounding Covariates in TriNetX: A Descriptive Analysis Analyses
Characterization of Confounding Covariates in TriNetX: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/trends-single-dose-doxycycline-lyme-disease-prophylaxis-1 Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Third Descriptive Analysis Analyses
Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Third Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-confounding-covariates-sentinel-distributed Characterization of Confounding Covariates in the Sentinel Distributed Database (SDD): A Descriptive Analysis Analyses
Characterization of Confounding Covariates in the Sentinel Distributed Database (SDD): A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/proportion-incident-syndrome-inappropriate-antidiuretic Proportion of Incident Syndrome of Inappropriate Antidiuretic Hormone Secretion Cases with Evidence of Pulmonary Opportunistic Infections Among New Users of BIC/FTC/TAF: A Descriptive Analysis Analyses
Proportion of Incident Syndrome of Inappropriate Antidiuretic Hormone Secretion Cases with Evidence of Pulmonary Opportunistic Infections Among New Users of BIC/FTC/TAF: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/characterization-confounding-covariate-data-capture-us-food Characterization of Confounding Covariate Data Capture in the U.S. Food and Drug Administration’s Sentinel Distributed Database Publications and Presentations
Characterization of Confounding Covariate Data Capture in the U.S. Food and Drug Administration’s Sentinel Distributed Database
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/single-dose-doxycycline-lyme-disease-prophylaxis-children Single-Dose Doxycycline for Lyme Disease Prophylaxis in Children in a Large United States Healthcare Database, 2016-2020 Publications and Presentations
Single-Dose Doxycycline for Lyme Disease Prophylaxis in Children in a Large United States Healthcare Database, 2016-2020
Publications and Presentations
https://www.sentinelinitiative.org/methods-data-tools/methods/use-case-2-uc2-aim-5-plasmode-simulation-based-quantitative-bias Use Case 2 (UC2) Aim 5: Plasmode Simulation Based Quantitative Bias Analysis (QBA) for Unmeasured Confounding Methods, Data, & Tools
Use Case 2 (UC2) Aim 5: Plasmode Simulation Based Quantitative Bias Analysis (QBA) for Unmeasured Confounding
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/biktarvy-bictegraviremtricitabinetenofovir-alafenamide Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) & Signal Identification Studies
Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) & Signal Identification
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-hormonal-contraceptives-following-live-birth-0 Utilization of Hormonal Contraceptives Following Live-Birth or Stillbirth Delivery: A Second Descriptive Analysis Assessments
Utilization of Hormonal Contraceptives Following Live-Birth or Stillbirth Delivery: A Second Descriptive Analysis
Assessments
https://www.sentinelinitiative.org/studies/drugs/new-molecular-entities-nmes New Molecular Entities (NMEs) & Utilization Characterization Studies
New Molecular Entities (NMEs) & Utilization Characterization
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-faricimab-use-self-controlled Outcome Monitoring Following Faricimab Use: A Self-Controlled Risk Interval Signal Identification Analysis Analyses
Outcome Monitoring Following Faricimab Use: A Self-Controlled Risk Interval Signal Identification Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/strengthening-inferential-studies-fda-sentinel-initiative Strengthening Inferential Studies in the FDA Sentinel Initiative: Results from a Methodological Demonstration Project Publications and Presentations
Strengthening Inferential Studies in the FDA Sentinel Initiative: Results from a Methodological Demonstration Project
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/enhancing-cause-death-prediction-development-and-validation Enhancing Cause of Death Prediction: Development and Validation of Machine Learning Models Using Multimodal Data Across Multiple Health-Care Sites Publications and Presentations
Enhancing Cause of Death Prediction: Development and Validation of Machine Learning Models Using Multimodal Data Across Multiple Health-Care Sites
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/intentional-self-harm-following-glucagon-peptide-1-2 Intentional Self-Harm Following Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RA) Use in Patients with Diabetes & Obesity: A Descriptive Analysis Analyses
Intentional Self-Harm Following Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RA) Use in Patients with Diabetes & Obesity: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/intentional-self-harm-following-glucagon-peptide-1-glp-1 Intentional Self-Harm Following Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Use in Patients 18 Years and Older: A Descriptive Analysis Analyses
Intentional Self-Harm Following Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Use in Patients 18 Years and Older: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/intentional-self-harm-algorithm-defined-intentional-3 Intentional Self-Harm Algorithm Defined in "Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes, By Age and Sex Subgroups: An Inverse Probability of Treatment Weighting Analysis" Methods, Data, & Tools
Intentional Self-Harm Algorithm Defined in "Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes, By Age and Sex Subgroups: An Inverse Probability of Treatment Weighting Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/intentional-self-harm-following-glucagon-peptide-1-1 Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes, By Age and Sex Subgroups: An Inverse Probability of Treatment Weighting Analysis Analyses
Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes, By Age and Sex Subgroups: An Inverse Probability of Treatment Weighting Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2021-second Duration of Follow Up for New Molecular Entities Approved in 2021: Second Descriptive Analysis Analyses
Duration of Follow Up for New Molecular Entities Approved in 2021: Second Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/assessing-treatment-effects-observational-data-missing-0 Assessing Treatment Effects in Observational Data With Missing Confounders: A Comparative Study of Practical Doubly-Robust and Traditional Missing Data Methods Publications and Presentations
Assessing Treatment Effects in Observational Data With Missing Confounders: A Comparative Study of Practical Doubly-Robust and Traditional Missing Data Methods
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/use-clinical-notes-assess-neuropsychiatric-events-after Use of Clinical Notes to Assess Neuropsychiatric Events After Montelukast Initiation Publications and Presentations
Use of Clinical Notes to Assess Neuropsychiatric Events After Montelukast Initiation
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/vabysmo-faricimab Vabysmo (Faricimab) & Signal Identification Studies
Vabysmo (Faricimab) & Signal Identification
Studies
https://www.sentinelinitiative.org/news-events/publications-presentations/evaluating-unmeasured-confounding-factors-claims-data-using Evaluating Unmeasured Confounding Factors in Claims Data Using Linked Electronic Health Records: A Proof-of-Principle Analysis Publications and Presentations
Evaluating Unmeasured Confounding Factors in Claims Data Using Linked Electronic Health Records: A Proof-of-Principle Analysis
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/symbravo-meloxicam-and-rizatriptan Assessment of ARIA Sufficiency: Symbravo (meloxicam and rizatriptan) Sufficiency Assessments
Assessment of ARIA Sufficiency: Symbravo (meloxicam and rizatriptan)
Sufficiency Assessments
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/renal-cell-carcinoma-algorithm-defined-renal-cell Renal Cell Carcinoma Algorithm Defined in "Renal Cell Carcinoma Following At Least 180 Days of Canagliflozin Use in Patients with Type 2 Diabetes Mellitus: A Clone-Censor-Weighted Analysis with Inverse Probability of Treatment Weighting for Active Comparators" Methods, Data, & Tools
Renal Cell Carcinoma Algorithm Defined in "Renal Cell Carcinoma Following At Least 180 Days of Canagliflozin Use in Patients with Type 2 Diabetes Mellitus: A Clone-Censor-Weighted Analysis with Inverse Probability of Treatment Weighting for Active Comparators"
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/renal-cell-carcinoma-following-least-180-days-canagliflozin Renal Cell Carcinoma Following At Least 180 Days of Canagliflozin Use in Patients with Type 2 Diabetes Mellitus: A Clone-Censor-Weighted Analysis with Inverse Probability of Treatment Weighting for Active Comparators Analyses
Renal Cell Carcinoma Following At Least 180 Days of Canagliflozin Use in Patients with Type 2 Diabetes Mellitus: A Clone-Censor-Weighted Analysis with Inverse Probability of Treatment Weighting for Active Comparators
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/statistical-methods-harmonize-electronic-health-record-data Statistical Methods to Harmonize Electronic Health Record Data Across Healthcare Systems: Case Study and Lessons Learned Publications and Presentations
Statistical Methods to Harmonize Electronic Health Record Data Across Healthcare Systems: Case Study and Lessons Learned
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/active-surveillance-medical-product-use-fda-s-sentinel-0 Active Surveillance of Medical Product Use in the FDA’s Sentinel System: A Focus on Pediatric Populations Publications and Presentations
Active Surveillance of Medical Product Use in the FDA’s Sentinel System: A Focus on Pediatric Populations
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/myqorzo-aficamten Assessment of ARIA Sufficiency: Myqorzo (aficamten) Sufficiency Assessments
Assessment of ARIA Sufficiency: Myqorzo (aficamten)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/fluoride Fluoride & Utilization Studies
Fluoride & Utilization
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-orally-ingestible-systemic-sodium-fluoride Utilization of Orally Ingestible Systemic Sodium Fluoride: A Descriptive Analysis Analyses
Utilization of Orally Ingestible Systemic Sodium Fluoride: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/beta-blockers Beta Blockers & Hypoglycemia Studies
Beta Blockers & Hypoglycemia
Studies
https://www.sentinelinitiative.org/studies/drugs/mother-infant-linkage-table Mother-Infant Linkage Table & Characterization Studies
Mother-Infant Linkage Table & Characterization
Studies
https://www.sentinelinitiative.org/news-events/publications-presentations/characterization-and-comparison-structured-and-unstructured Characterization and Comparison of Structured and Unstructured Electronic Health Record Data Mapped to MedDRA for Post-Marketing Surveillance Publications and Presentations
Characterization and Comparison of Structured and Unstructured Electronic Health Record Data Mapped to MedDRA for Post-Marketing Surveillance
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/systematic-process-assessing-fitness-purpose-health-outcomes A Systematic Process for Assessing Fitness-for-Purpose of Health Outcomes for Computable Phenotyping With Electronic Health Record Data Publications and Presentations
A Systematic Process for Assessing Fitness-for-Purpose of Health Outcomes for Computable Phenotyping With Electronic Health Record Data
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/association-glp-1-receptor-agonists-intentional-self-harm Association of GLP-1 Receptor Agonists with Intentional Self-Harm in Patients with Type 2 Diabetes: A Sentinel Distributed Database Study Publications and Presentations
Association of GLP-1 Receptor Agonists with Intentional Self-Harm in Patients with Type 2 Diabetes: A Sentinel Distributed Database Study
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/doxycycline Doxycycline & Lyme Disease Studies
Doxycycline & Lyme Disease
Studies
https://www.sentinelinitiative.org/studies/characterization-influenza-complications-among-individuals-diagnosed-influenza-illness-0 Characterization of Influenza Complications Among Individuals Diagnosed with Influenza-Like Illness in Outpatient, Ambulatory, and Emergency Department Settings: A Descriptive Analysis Analyses
Characterization of Influenza Complications Among Individuals Diagnosed with Influenza-Like Illness in Outpatient, Ambulatory, and Emergency Department Settings: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/serious-infection-crohns-disease-patients-treated Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative Publications and Presentations
Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/glucagon-peptide-1-receptor-agonists Glucagon-Like Peptide-1 Receptor Agonists & Intentional Self-Harm Studies
Glucagon-Like Peptide-1 Receptor Agonists & Intentional Self-Harm
Studies
https://www.sentinelinitiative.org/methods-data-tools/sentinel-common-data-model/data-quality-review-and-characterization-programs Data Quality Review and Characterization Programs Methods, Data, & Tools
Data Quality Review and Characterization Programs
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/routine-querying-tools/sentinel-routine-querying-system Sentinel Routine Querying System Methods, Data, & Tools
Sentinel Routine Querying System
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/serious-infection-algorithm-defined-serious-infection-0 Serious Infection Algorithm Defined in "Serious Infection Following Ustekinumab Use in Patients with Ulcerative Colitis: An Inverse Probability of Treatment Weighting Analysis" Methods, Data, & Tools
Serious Infection Algorithm Defined in "Serious Infection Following Ustekinumab Use in Patients with Ulcerative Colitis: An Inverse Probability of Treatment Weighting Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/serious-infection-following-ustekinumab-use-patients Serious Infection Following Ustekinumab Use in Patients with Ulcerative Colitis: An Inverse Probability of Treatment Weighting Analysis Analyses
Serious Infection Following Ustekinumab Use in Patients with Ulcerative Colitis: An Inverse Probability of Treatment Weighting Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-ozempic-use-patients-type-2-0 Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: An Active Comparator Signal Identification Analysis Analyses
Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: An Active Comparator Signal Identification Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/motegrity-prucalopride Motegrity (Prucalopride) & Signal Identification Studies
Motegrity (Prucalopride) & Signal Identification
Studies
https://www.sentinelinitiative.org/studies/drugs/trulance-plecanatide Trulance (Plecanatide) & Signal Identification Studies
Trulance (Plecanatide) & Signal Identification
Studies
https://www.sentinelinitiative.org/studies/drugs/semaglutide-injectables Semaglutide Injectables & Signal Identification Studies
Semaglutide Injectables & Signal Identification
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-prucalopride-and-plecanatide Outcome Monitoring Following Prucalopride and Plecanatide Use: An Active Comparator Signal Identification Analysis with Alternating Exposure-Comparator Roles Analyses
Outcome Monitoring Following Prucalopride and Plecanatide Use: An Active Comparator Signal Identification Analysis with Alternating Exposure-Comparator Roles
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/risk-gastrointestinal-hypomotility-constipation-or-gi Risk of Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications and Intentional Self-Harm in Individuals with Migraine Following Use of CGRP Inhibitors: A Propensity Score Matched Analysis Analyses
Risk of Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications and Intentional Self-Harm in Individuals with Migraine Following Use of CGRP Inhibitors: A Propensity Score Matched Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/expedited-chart-review-process-large-database-studies-using An Expedited Chart Review Process for Large Database Studies Using Natural Language Processing and Multi-Wave Adaptive Sampling Publications and Presentations
An Expedited Chart Review Process for Large Database Studies Using Natural Language Processing and Multi-Wave Adaptive Sampling
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/calcitonin-gene-related-peptide-cgrp-inhibitors Calcitonin Gene-Related Peptide (CGRP) Inhibitors & Gastrointestinal Hypomotility, Constipation or GI dysmotility with Serious Complications and Intentional Self-Harm Studies
Calcitonin Gene-Related Peptide (CGRP) Inhibitors & Gastrointestinal Hypomotility, Constipation or GI dysmotility with Serious Complications and Intentional Self-Harm
Studies
https://www.sentinelinitiative.org/news-events/publications-presentations/health-information-exchanges-hies-novel-sources-population Health Information Exchanges (HIEs) as Novel Sources for Population-Based Post Marketing Surveillance of Medical Products: A Pilot Study from the FDA Sentinel Innovation Center Publications and Presentations
Health Information Exchanges (HIEs) as Novel Sources for Population-Based Post Marketing Surveillance of Medical Products: A Pilot Study from the FDA Sentinel Innovation Center
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/confounding-covariates Confounding Covariates & Characterization Studies
Confounding Covariates & Characterization
Studies
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/gastrointestinal-hypomotility-algorithm-defined-risk Gastrointestinal Hypomotility Algorithm Defined in "Risk of Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications and Intentional Self-Harm in Individuals with Migraine Following Use of CGRP Inhibitors: A Propensity Score Matched Analysis" Methods, Data, & Tools
Gastrointestinal Hypomotility Algorithm Defined in "Risk of Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications and Intentional Self-Harm in Individuals with Migraine Following Use of CGRP Inhibitors: A Propensity Score Matched Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/constipation-algorithm-defined-risk-gastrointestinal Constipation Algorithm Defined in "Risk of Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications and Intentional Self-Harm in Individuals with Migraine Following Use of CGRP Inhibitors: A Propensity Score Matched Analysis" Methods, Data, & Tools
Constipation Algorithm Defined in "Risk of Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications and Intentional Self-Harm in Individuals with Migraine Following Use of CGRP Inhibitors: A Propensity Score Matched Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/gastrointestinal-hypomotility-constipation-or-gi Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications Algorithm Defined in "Risk of Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications and Intentional Self-Harm in Individuals with Migraine Following Use of CGRP Inhibitors: A Propensity Score Matched Analysis" Methods, Data, & Tools
Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications Algorithm Defined in "Risk of Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications and Intentional Self-Harm in Individuals with Migraine Following Use of CGRP Inhibitors: A Propensity Score Matched Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/intentional-self-harm-algorithm-defined-risk Intentional Self-Harm Algorithm Defined in "Risk of Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications and Intentional Self-Harm in Individuals with Migraine Following Use of CGRP Inhibitors: A Propensity Score Matched Analysis" Methods, Data, & Tools
Intentional Self-Harm Algorithm Defined in "Risk of Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications and Intentional Self-Harm in Individuals with Migraine Following Use of CGRP Inhibitors: A Propensity Score Matched Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/paralytic-ileus-or-intestinal-obstruction-without Paralytic Ileus or Intestinal Obstruction Without Hernia Algorithm Defined in "Risk of Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications and Intentional Self-Harm in Individuals with Migraine Following Use of CGRP Inhibitors: A Propensity Score Matched Analysis" Methods, Data, & Tools
Paralytic Ileus or Intestinal Obstruction Without Hernia Algorithm Defined in "Risk of Gastrointestinal Hypomotility, Constipation, or GI Dysmotility with Serious Complications and Intentional Self-Harm in Individuals with Migraine Following Use of CGRP Inhibitors: A Propensity Score Matched Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/combined-hormonal-contraceptives Combined Hormonal Contraceptives & Venous Thromboembolism Studies
Combined Hormonal Contraceptives & Venous Thromboembolism
Studies
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/venous-thromboembolism-algorithm-defined-use-combined Venous Thromboembolism Algorithm Defined in "Use of Combined Hormonal Contraceptives or Progestin-only Contraceptives During 6-month Postpartum Period and the Risk of Venous Thromboembolism: A Propensity Score Matched Analysis" Methods, Data, & Tools
Venous Thromboembolism Algorithm Defined in "Use of Combined Hormonal Contraceptives or Progestin-only Contraceptives During 6-month Postpartum Period and the Risk of Venous Thromboembolism: A Propensity Score Matched Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-combined-hormonal-contraceptives-or-progestin-only Use of Combined Hormonal Contraceptives or Progestin-only Contraceptives During 6-month Postpartum Period and the Risk of Venous Thromboembolism: A Propensity Score Matched Analysis Analyses
Use of Combined Hormonal Contraceptives or Progestin-only Contraceptives During 6-month Postpartum Period and the Risk of Venous Thromboembolism: A Propensity Score Matched Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/stroke-and-bleeding-risks-non-vitamin-k-oral-anticoagulants Stroke and Bleeding Risks with Non-Vitamin K Oral Anticoagulants in Nonvalvular Atrial Fibrillation Publications and Presentations
Stroke and Bleeding Risks with Non-Vitamin K Oral Anticoagulants in Nonvalvular Atrial Fibrillation
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/counts-and-characterization-mortality-capture-among-long Counts of and Characterization of Mortality Capture Among Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis Analyses
Counts of and Characterization of Mortality Capture Among Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/mortality-following-long-acting-injectable-antipsychotics-0 Mortality Following Long-Acting Injectable Antipsychotics Use: An Updated Inverse Probability of Treatment Weighting Analysis Assessments
Mortality Following Long-Acting Injectable Antipsychotics Use: An Updated Inverse Probability of Treatment Weighting Analysis
Assessments
https://www.sentinelinitiative.org/studies/drugs/long-acting-injectable-antipsychotics Long-Acting Injectable Antipsychotics & Mortality Studies
Long-Acting Injectable Antipsychotics & Mortality
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/mortality-following-long-acting-injectable-antipsychotics-1 Mortality Following Long-Acting Injectable Antipsychotics Use: A Third Inverse Probability of Treatment Weighting Analysis Analyses
Mortality Following Long-Acting Injectable Antipsychotics Use: A Third Inverse Probability of Treatment Weighting Analysis
Analyses